Aurinia Pharmaceuticals Inc (STU:IKAP)
€ 9.252 -0.386 (-4%) Market Cap: 1.32 Bil Enterprise Value: 1.07 Bil PE Ratio: 0 PB Ratio: 3.73 GF Score: 84/100

Aurinia Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 12, 2023 / 12:30AM GMT
Release Date Price: €7.82 (+8.82%)
Matthew Bannon

All right. welcome to the 41st Annual JPMorgan Healthcare Conference. My name is Matt Bannon, and I'm a banker here at JPM. I'm really excited to be setting the stage for our next presenting company, Aurinia Pharmaceuticals. And on behalf of Aurinia, we have CEO, Peter Greenleaf. So Peter, the stage is yours.

Peter S. Greenleaf
Aurinia Pharmaceuticals Inc. - President, CEO & Director

Thanks, Matt, and thanks to JPMorgan for having us here at the conference this year. Looking forward to the next 40 minutes or so between the presentation and the Q&A to update you all on our progress as a company as we enter the new year. And we've had some good news entering it, so I look forward to updating you on all fronts for the company.

Before I do, of course, I want to just point you to our forward-looking statements and as well for most -- our most recent filings with the FDA, to just point you to our site at aurinia.com and our Investors section there.

If you don't know who the organization is, a good place to start is we're a fully

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot